Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Results for the Phase I/II study of anti-CD3 x anti-HER2/Neu BATs with Pembrolizumab in metastatic breast cancer were posted, detailing dose-limiting toxicities, response rates, survival metrics, and immune monitoring data. Related study documents, including the Study Protocol and Informed Consent Form, were added.
    Difference
    3%
    Check dated 2026-03-05T23:26:40.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    Revision: v3.4.2 replaces v3.4.1 on the page; there are no visible changes to the study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T07:33:53.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1. No user-visible changes to study details or page content.
    Difference
    0.1%
    Check dated 2026-02-05T05:52:24.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a Show glossary option and the label 'Last Update Submitted that Met QC Criteria' with a revision note 'Revision: v3.4.0'. Removed 'No FEAR Act data' and updated capitalization of related labels.
    Difference
    0.2%
    Check dated 2026-01-28T02:56:14.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page revision history was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:09:32.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added a Locations section with Virginia and its details; removed the HHS Vulnerability Disclosure and Virginia Locations, and updated to Revision: v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T09:14:12.000Z thumbnail image

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.